|Day Low/High||67.57 / 68.30|
|52 Wk Low/High||67.28 / 88.49|
Wall Street scores a trifecta of record closes on Monday as a crude oil rally gives stocks an across-the-board boost.
Wall Street is on track for record closes for all the benchmark indices as crude oil resumes its rally.
Stocks are higher on Monday as an early-morning surge in crude oil prices plateaus around $47 a barrel.
U.S. stocks rose early Monday as investors parsed comments from oil officials in Iran and Iraq, hinting at a production cut at next week's OPEC meeting.
Stock futures edge higher on Monday morning as investors pin hopes on a production freeze agreement among major oil producers.
European stocks turned positive amid bullish oil sentiment ahead of November 30 OPEC meeting.
Novartis is entering into talks to purchase Amneal Pharmaceuticals in a deal that could value the company at $8 billion.
Jim Cramer says take a pass on TGT and the dollar stores; look at AMZN instead.
Jim Cramer honors veterans and those willing to invest in a brighter future for America.
A sale or spinoff of this business will likely get the attention of competitors that want to increase their over-the-counter product units.
Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.
The biotech company cancelled its conference appearance and took its time filing its Form 10-Q with the Securities and Exchange Commission.
We have to ask: where is the cash flow to pay off the debt, if any important prices are rolled back?
Tech giants, Big Pharma and insurers are all angling to profit from the $3 trillion-plus U.S. healthcare market.
Britain's largest pharmaceuticals company reports growth in its HIV medicines business as it submits a shingles vaccine for FDA approval.
The U.K. currency falls to its lowest intra-day level since the Oct. 7 'flash crash' before testimony from Bank of England Governor Mark Carney.
The chip maker sinks on news of production problems and a gloomy fourth-quarter prognosis.
The group's blood cancer drug Gleevec also holds up better than expected against generic competition.
Forward-looking purchasing managers' indices and earnings from beleaguered lender Deutsche Bank feature among the other release highlights.
Novartis stock has fallen 14% in the last year. A wave of generic drugs has wrecked results.
Shares in the stock decline only marginally as the pharmaceuticals group sticks with its full-year forecast.
Wall Street sells off as a disappointing quarterly performance from Alcoa heralds a poor start to the third-quarter earnings season and crude oil retreats from highs.
Stock losses accelerate on Tuesday afternoon as a disappointing quarterly performance from Alcoa heralds a poor start to the third-quarter earnings season.
Both it and Ligand Pharmaceuticals look significantly undervalued relative to their prospects.
A KeyBanc Capital Markets analyst increases his price target on the stock to $221 from $199.
Here are Friday's top research calls, including upgrades for Casey's and Qualcomm and downgrades for AutoZone and Mylan.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CPHD, KODK, PINC, SRLP Downgrades: APU, ATU, AZO, BDL, GATX, GRA, HLT, MYL, NVS, TI.A, VG Initiations: None Read on to get TheStreet Quant Ratings' detailed report: